Upper Airway Dysfunction-Related Cardiovascular Diseases Laboratory
Since its establishment in August 2015, the Upper Airway Dysfunction-Related Cardiovascular Diseases Laboratory has carried out studies on the pathogenesis and transformation of metabolism-related cardiopulmonary vascular diseases, aiming to explore the roles and mechanisms of lipid metabolism-related, oxygen metabolism related, and glucose metabolism-related disorders in cardiopulmonary vascular diseases.
Research is currently underway to clarify the effects of metabolic abnormalities on the pathogenesis and transformation of cardiopulmonary vascular diseases. Genomics, transcriptomics, metabonomics, and proteomics have been employed to determine the omic characteristics of cardiovascular diseases related to lipid metabolism, oxygen metabolism, and glucose metabolism, and to identify biomarkers and establish risk prediction models. For this, laboratory disease models for myocardial ischemia, aortic aneurysm, atherosclerosis, and pulmonary hypertension. have been established in the Laboratory. Studies are underway to determine: the roles of ANGPTLs, which are familial hypercholesterolemia and dyslipidemia-related proteins, in atherosclerotic cardiovascular disease; the role of serum exosomes in hypoxia-induced hypertension; the role of cardioprotective adipokine CTRP9 in ischemic heart disease under hypoxic conditions; the molecular mechanisms of glucose and lipid metabolism disorders and insulin resistance in cardiovascular diseases and Chinese medicine interventions; the roles of inflammation in muscle injury and heart injury; and the changes in intestinal microflora in cardiovascular diseases under ischemia or hypoxia.
